N-methyl-1-(4-(trifluoromethyl)benzyl)-piperidine-4-amine | 1080651-54-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-methyl-1-(4-(trifluoromethyl)benzyl)-piperidine-4-amine
• 英文别名: N-methyl-1-(4-(trifluoromethyl)benzyl)piperidine-4-amine；N-methyl-1-[[4-(trifluoromethyl)phenyl]methyl]piperidin-4-amine
• CAS: 1080651-54-2
• 化学式: C₁₄H₁₉F₃N₂
• 分子量: 272.313
• InChiKey: GDIOKJCVUZZFRW-UHFFFAOYSA-N

物化性质

• 沸点：
  305.5±42.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-methyl-1-(4-(trifluoromethyl)benzyl)-piperidine-4-amine 在 水 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-methyl-4-[2-[methyl-[1-[[4-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]amino]-2-oxoethyl]benzamide
  参考文献：
  名称：

  新型GPR119激动剂的发现，优化和体内评估

  摘要：

  GPR119越来越被视为治疗II型糖尿病和代谢综合征其他成分的有吸引力的靶标。在一项旨在开发GPR119受体激动剂的计划中，我们鉴定了具有降低hERG抑制作用的有效化合物，具有良好的药代动力学特性以及在体内具有出色的降糖效果的化合物。但是，在GPR119敲除（KO）小鼠模型中进行的进一步分析显示，其生物学效应并不完全是由于GPR119激动作用，这突出了转基因动物在药物发现计划中的价值。

  DOI：

  10.1016/j.bmcl.2011.10.033
• 作为产物：
  描述：

  4-N-叔丁氧羰基-4-N-甲基氨基哌啶 在 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 N-methyl-1-(4-(trifluoromethyl)benzyl)-piperidine-4-amine
  参考文献：
  名称：

  新型GPR119激动剂的发现，优化和体内评估

  摘要：

  GPR119越来越被视为治疗II型糖尿病和代谢综合征其他成分的有吸引力的靶标。在一项旨在开发GPR119受体激动剂的计划中，我们鉴定了具有降低hERG抑制作用的有效化合物，具有良好的药代动力学特性以及在体内具有出色的降糖效果的化合物。但是，在GPR119敲除（KO）小鼠模型中进行的进一步分析显示，其生物学效应并不完全是由于GPR119激动作用，这突出了转基因动物在药物发现计划中的价值。

  DOI：

  10.1016/j.bmcl.2011.10.033

文献信息

• Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands
  申请人：Hendrix James A.

  公开号：US20090247509A1

  公开（公告）日：2009-10-01

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，其表现出对多巴胺D3受体的选择性结合。另一方面，本发明涉及一种治疗与多巴胺D3受体活性相关的中枢神经系统疾病的方法，该方法包括向需要此类治疗的患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神疾病、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞引起的迟发性运动障碍、吉尔斯-德-拉-图雷综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备所述化合物的方法以及将所述化合物作为多巴胺D3受体成像剂的制备和使用方法。
• Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
  申请人：Hendrix A. James

  公开号：US20070161641A1

  公开（公告）日：2007-07-12

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates is to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，其具有选择性地与多巴胺D3受体结合。另一方面，本发明涉及一种治疗中枢神经系统疾病的方法，该疾病与多巴胺D3受体活性有关，包括对患者进行治疗，向患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神病性障碍、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞剂引起的迟发性运动障碍、吉尔·德·拉·图雷特综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及所述化合物的制备过程，以及将所述化合物作为多巴胺D3受体成像剂的制备和使用方法。
• NITROGEN-CONTAINING SIX-MEMBERED AROMATIC RING DERIVATIVES AND PHARMACEUTICAL PRODUCTS CONTAINING THE SAME
  申请人：Takemoto Naohiro

  公开号：US20100130739A1

  公开（公告）日：2010-05-27

  Provided is a compound that has the ability to promote axonal outgrowth in combination with the ability to promote angiogenesis and can therefore be used to reduce central nerve injuries such as head injury and spinal cord injury, cerebral infarction, ischemic heart diseases such as myocardial infarction and organic angina, peripheral arterial occlusive diseases such as critical limb ischemia, or after-effects of these diseases. Specifically, the compound is represented by the following formula (I): in which Nx group is preferably a 6-membered aromatic ring containing two nitrogen atoms; R 0 , R 1 and R 2 are each independently a hydrogen atom, an alkyl group, an amino group or the like; E is an oxygen atom or an —NR 8 group (wherein R 8 is an alkyl group or the like); n is an integer of 0 to 5; X and Y are each a connecting bond, a cycloalkyl group, —CO— or the like; and Q is a hydrogen atom or a phenyl group.

  提供的是一种化合物，具有促进轴突生长和促进血管生成的能力，因此可用于减少中枢神经损伤，如头部损伤和脊髓损伤，脑梗死，缺血性心脏病，如心肌梗死和器质性心绞痛，周围动脉闭塞性疾病，如严重肢体缺血或这些疾病的后遗症。具体而言，该化合物由以下公式（I）表示： 其中，Nx基团最好是含有两个氮原子的6元芳香环；R0、R1和R2分别独立地是氢原子、烷基、氨基或类似物；E是氧原子或—NR8基团（其中，R8是烷基或类似物）；n是0到5的整数；X和Y分别是连接键、环烷基、—CO—或类似物；Q是氢原子或苯基。
• Nitrogen-containing six-membered aromatic ring derivatives and pharmaceutical products containing the same
  申请人：Takemoto Naohiro

  公开号：US08685989B2

  公开（公告）日：2014-04-01

  Compounds of Formula (I) promote axonal outgrowth angiogenesis and can therefore be used to reduce central nerve injuries such as head injury and spinal cord injury, cerebral infarction, ischemic heart diseases, peripheral arterial occlusive diseases, or after-effects of these diseases. in which Nx group is preferably a 6-membered aromatic ring containing two nitrogen atoms; R0, R1 and R2 are each independently a hydrogen atom, an alkyl group, or an amino group; E is an oxygen atom or an —NR8 group (wherein R8 is an alkyl group or the like); n is an integer of of 0 to 5; X and Y are each a connected bond, a cycloalkyl group, or —CO—; and Q is a hydrogen atom or a phenyl group.

  公式（I）的化合物促进轴突生长和血管生成，因此可用于减少中枢神经损伤，例如头部损伤和脊髓损伤，脑梗塞，缺血性心脏病，周围动脉闭塞病或这些疾病的后遗症。其中Nx基团最好是含有两个氮原子的6元芳香环；R0，R1和R2分别是氢原子，烷基或氨基；E是氧原子或-NR8基团（其中R8是烷基或类似物）；n是0到5的整数；X和Y分别是连接键，环烷基或-CO-；Q是氢原子或苯基。
• Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
  申请人：Aventis Pharmaceuticals Inc.

  公开号：EP1935887A1

  公开（公告）日：2008-06-25

  The invention relates to heterocyclic substituted carbonyl derivatives of the formula I that display selective binding to dopamine D3 receptors and are useful for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D3 receptors.

  本发明涉及式 I 的杂环取代的羰基衍生物 本发明涉及式 I 的杂环取代羰基衍生物，该衍生物与多巴胺 D3 受体具有选择性结合，可用于治疗需要此类治疗的患者中与多巴胺 D3 受体活性相关的中枢神经系统紊乱，包括向受试者施用治疗有效量的所述化合物以缓解此类紊乱。可用这些化合物治疗的中枢神经系统疾病包括精神障碍、药物依赖、药物滥用、运动障碍（如帕金森病、帕金森氏症、神经抑制剂诱发的迟发性运动障碍、吉勒-德拉图雷特综合征和亨廷顿氏病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及本文所述化合物的制备过程以及将这些化合物用作多巴胺 D3 受体成像剂的制备和使用方法。